ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024. Jefferies Global Healthcare Conference Presentation Time Wednesday, June 5 at 9:30 a.m. EST Presenters Raj Kannan, CEO; Louie Naumovski, Interim CMO ...

Table of Contents IMAB The Nasdaq Stock Market LLC (The Nasdaq Global Market) The Nasdaq Stock Market LLC (The Nasdaq Global Market) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( ...

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the "Transaction") have been either satisfied or waived and accordingly, the Transaction has successfully closed. The Company trans ...

Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inhibitors for patients with newly diagnosed NSCLC in 1H 2024 First patient dosed in an ongoing, triplet combination, dose escalation study of givastomig (CLDN18.2x4-1BB bispecific antibody) in 1Q 2024 RMB2.3 billion (US$321 ...

MF3d I-Mab (NASDAQ:IMAB) Biopharma is a clinical-stage biotech company with a focus on immunotherapies and oncology. The company recently announced that it has signed agreement to divest its assets and business operations in China (the Hangzhou Company) to become a U.S-based biotech company. After the divesting, I-Mab will have a healthy balance sheet with more than $400 million in cash, a pipeline consists of three potential best-in-class clinical stage oncology assets, the potential to receive up to $ ...

Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech  Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reducing operational costs, and mitigating potential associated risks The Company retains cash in hand, ex-China rights of all clinical stage assets led by givastomig (CLDN18.2/4-1BB), uliledlimab (CD73), and TJ-L14B (PD-L1/4-1 ...

I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript August 17, 2023 8:00 AM ET Company Participants Tyler Ehler - Senior Director for IR Raj Kannan - CEO John Hayslip - CMO Richard Yeh - Interim CFO and COO Andrew Zhu - President and Head of R&D Conference Call Participants Kelly Shi - Jefferies Joe Catanzaro - Piper Sandler Louise Chen - Cantor Fitzgerald Gil Blum - Needham & Company Andres Maldonado - H.C. Wainwright Xiaoyi Qu - CICC Bing Zhao - China Renaissance Zhuxuan Jiang - CITIC Securities Tyler Eh ...

Table of Contents Title of Each Class Trading SymbolName of Each Exchange On Which Registered American depositary shares, each ten (10) American depositary shares representing twenty-three (23) ordinary shares Ordinary shares, par value US$0.0001 per share* IMAB The Nasdaq Stock Market LLC (The Nasdaq Global Market) The Nasdaq Stock Market LLC (The Nasdaq Global Market) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 1 ...

Exhibit 99.1 Shanghai (HQ) Suites 802, 505, 702, West Tower 88 Shangke Road, Pudong New District Shanghai, China United States Suite 710, 9801 Washingtonian Blvd Gaithersburg Maryland 20878 1 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 · Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rat ...

I-Mab (NASDAQ:IMAB) Q4 2022 Earnings Conference Call March 31, 2023 8:15 AM ET Company Participants Tyler Ehler - Senior Director of Investor Relations Andrew Zhu - Acting Chief Executive Officer Richard Yeh - Interim Chief Financial Officer and Chief Operating Officer Jingwu Zang - Founder and Chairman Conference Call Participants Kelly Shi - Jefferies Joseph Catanzaro - Piper Sandler Louise Chen - Cantor Fitzgerald Andres Maldonado - H.C. Wainwright Tyler Ehler Good morning to everyone and thank you for j ...